June 28, 2011

Mipomersen Data Presented at European Atherosclerosis Society Congress

- Phase 3 Studies Highlight Investigational Drug’s Potential in Lowering Lp(a) and Reducing Necessity for Lipid-Apheresis -

 

Mipomersen Data Presented at European Atherosclerosis Society Congress
- Phase 3 Studies Highlight Investigational Drug’s Potential in Lowering Lp(a) and Reducing Necessity for Lipid-Apheresis -

Paris, France, and Carlsbad, California – June 28, 2011 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced today that two additional analyses from phase 3 studies of mipomersen were presented at the 79th European Atherosclerosis Society (EAS) Congress.